Loading
A phase 2 trial of Doxorubicin, Ifosfamide in vascular tumours and epithelioid sarcoma, run by HRYZ Biotech Co., now recruiting.
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06277154 by HRYZ Biotech Co., with 148 participants planned, started 2024-02-21 and due to reach its primary completion in 2026-02. Interventions recorded: MASCT-I, Doxorubicin, Ifosfamide. Conditions listed: Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Uterine sarcoma, Doxorubicin, Cytotoxic chemotherapy.
Shares Ifosfamide, Doxorubicin, Cytotoxic chemotherapy.
Shares Ifosfamide, Doxorubicin, Cytotoxic chemotherapy.
Shares Uterine sarcoma, Doxorubicin, Cytotoxic chemotherapy.
Shares Ifosfamide, Doxorubicin, Cytotoxic chemotherapy.
Shares Epithelioid sarcoma, Doxorubicin.
Shares Rhabdomyosarcoma, Ifosfamide.
Shares Ifosfamide, Doxorubicin, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/